Video

Platinum Sensitivity and PARP Inhibition in Ovarian Cancer

Related Videos
Kimberly Cannavale, MPH
Jean-Marc Classe, MD, PhD, Nantes Université
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Emil Lou, MD, PhD, FACP
Amma Asare, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD
Vaidehi Mujumdar, MD
Erin Crane, MD, MPH
Related Content
FDA
June 17th 2024

FDA Approves Pembrolizumab Plus Chemotherapy for Advanced/Recurrent Endometrial Carcinoma

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Eric Vallieres, MD, FRCSC, of Swedish Medical Center
June 13th 2024

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Angeles Alvarez Secord, MD, MHSc
June 6th 2024

Mirvetuximab Soravtansine Meets Primary End Point of PICCOLO Trial in FRα-High, Platinum-Sensitive Ovarian Cancer

Petosemtamab Combo in HNSCC | ©Lars Neumann- stock.adobe.com
June 4th 2024

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC